Scalper1 News
The M&A action in specialty pharma continued Monday as Allergan (AGN) formally rejected a takeover offer while offering bullish guidance, and Shire (SHPG) got into the fatty-liver disease game by acquiring Lumena Pharmaceuticals. Allergan’s board unanimously rejected Valeant Pharmaceuticals’ (VRX) unsolicited $47 billion bid, not only charging that it undervalues the company but questioning the sustainability of Valeant’s buyout-driven business Scalper1 News
Scalper1 News